A promising anticancer drug developed by the Christus Stehlin Foundation for Cancer Research in Houston is being tested on patients after quickly receiving approval from the U.S. Food and Drug Administration for Phase I clinical trials.
A promising anticancer drug developed by the Christus Stehlin Foundation for Cancer Research in Houston is being tested on patients after quickly receiving approval from the U.S. Food and Drug Administration for Phase I clinical trials.
